Physiomics develops computer simulation technology to understand and predict patient responses to pharmaceuticals. The Company combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, Physiomics' lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical trials, which improves the efficacy of combinations in pre-clinical xenografts.